Accuray, manufacturer of the CyberKnife® Robotic Radiosurgery System, recently presented new data that demonstrates the CyberKnife System’s effectiveness in treating central nervous system (CNS) tumors.
CNS tumors are abnormal growths of cells in the brain or spinal cord. They can be benign (non-cancerous) or malignant (cancerous) and can vary widely in their characteristics, growth rates, and impact on brain function. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States.
The data was presented at the 2025 Radiosurgery Society (RSS) Scientific Meeting, held in Tucson, Arizona. The RSS is an international, medical professional, non-profit society consisting of physicians, physicists, and healthcare professionals dedicated to advancing the education, science, and clinical practice of stereotactic radiosurgery, stereotactic body radiation therapy, and advancing therapies.
Key findings from the study include:
- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments.
- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases.
- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination.
- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief.
At Louisville CyberKnife, we treat CNS tumors with radiation therapy using the CyberKnife® Robotic Radiosurgery System. The CyberKnife System’s innovative technology delivers robotic-precision, high-dose radiation therapy, minimizing damage to surrounding healthy tissue. The safe and effective treatments are quick, non-invasive, and have little to no side effects or recovery time.
To learn more about CyberKnife treatment, or to schedule a consultation, please contact Louisville CyberKnife today.